Type 2 Diabetes: Understanding its Early Drivers and the Road to Therapeutics

摘要 要求支持一个关键研讨会会议题为2型糖尿病：了解其早期 司机和治疗之路，由克里斯托弗罗兹博士，劳拉海斯勒和马丁迈尔斯组织。 会议将于2023年5月1日至4日在加州棕榈泉举行。 早期发现和相应的干预是良好治疗结果和避免并发症的关键。 大多数疾病的并发症。可以说，这可能不是2型糖尿病（T2 D）的情况， 血糖和HbA 1C升高的测量也会发生，这在历史上与视网膜病变的预测发作有关 在疾病的发病机制中处于晚期。这使得需要改进的T2 D标志物， 更好地诊断和治疗这种流行病的早期阶段。随着精准医疗的出现， 是时候在分子水平上重新研究2型糖尿病（前驱）的发病机制了。然而，问题 字段保持不变，例如：1. T2 D的哪些子集定义了某些糖尿病的进展率 并发症; 2.疾病的早期分子驱动因素是否可以更好地识别; 3.哪些因素导致 器官间通讯功能障碍和代谢稳态改变; 4.胰腺癌细胞衰竭 真正定义疾病; 5.如果发现得足够早，我们是否可以设想扭转，甚至防止 2型糖尿病？银线是，随着几种常用的T2 D疗法即将关闭专利，这可能只是 可以想象。尽管如此，仍然需要更有效的治疗方法，而不仅仅是 对于T2 D，以及它的合并症。因此，本次Keystone研讨会将审查当前的 T2 D发病机制和治疗前景的知识，以及对早期诊断的愿景， 作为，朝着更有效和更有针对性的T2 D治疗方案，也可以预防（或显著延迟） 导致并发症和合并症的途径。

ABSTRACT Support is requested for a Keystone Symposia conference entitled Type 2 Diabetes: Understanding its Early Drivers and the Road to Therapeutics, organized by Drs. Christopher Rhodes, Lora Heisler, and Martin Myers. The conference will be held in Palm Springs, CA from May 1 - 4, 2023. Early detection and consequential intervention are key to good treatment outcomes and avoidance of complications for most diseases. Arguably, this may not be the case for Type-2 diabetes (T2D) where measures of elevated glucose and HbA1C, historically related to a predicted onset of retinopathy, occur too late in the pathogenesis of the disease. This makes the need for improved markers of T2D necessary to better diagnose and treat this prevalent disease at early stages. With the advent of precision medicine, now is the time to re-examine the pathogenesis of type 2 (pre)diabetes at the molecular level. However, questions the field remain, such as: 1. Which subsets of T2D define the rate of progression to certain diabetes complications; 2. Can early molecular drivers of the disease be better identified; 3. What factors contribute to dysfunctional inter-organ communication and altered metabolic homeostasis; 4. Does pancreatic ß-cell failure really define the disease; and 5. If detected early enough, can we envision ways to reverse, or even prevent T2D? The silver lining is that with several commonly used T2D therapies coming off patent soon, this may just be conceivable. Nonetheless, there also remains a need for more effective therapeutic approaches, not just for T2D, but also for its comorbidities. Therefore, this Keystone Symposia conference will examine the current knowledge of T2D pathogenesis and the therapeutic landscape with a vision towards earlier diagnosis, as well as, towards more effective and tailored T2D treatment regime(s) that could also prevent (or significantly delay) the pathway to complications and comorbidities.